文献速递白血病

达沙替尼/泼尼松诱导后布林妥莫单抗/达沙替尼治疗Ph+急性淋巴细胞白血病

Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia.
PubMed 文献 · Blood Adv · 2023-01-01

该试验评估布林妥莫单抗联合达沙替尼和类固醇在65岁及以上Ph+或Ph样急性淋巴细胞白血病患者中的可行性与结局。诱导为达沙替尼/泼尼松,第56天未缓解者接受布林妥莫单抗再诱导,缓解者接受3周期布林妥莫单抗/达沙替尼缓解后治疗及达沙替尼/泼尼松维持。24例新诊断Ph+患者中位年龄73岁,中位随访2.7年,3年总生存率87%,无病生存率77%。

要点

  • 65岁及以上Ph+或Ph样急性淋巴细胞白血病患者可接受达沙替尼/泼尼松诱导。
  • 第56天未达缓解者接受布林妥莫单抗再诱导,缓解者接受3周期布林妥莫单抗/达沙替尼及达沙替尼/泼尼松维持。
  • 24例新诊断Ph+患者中位随访2.7年,3年总生存率87%、无病生存率77%。

核心结论

  • 该联合方案安全可行,虽需更长随访,但结果令人鼓舞,未来试验正基于此骨架方案开展。

研究设计与样本

  • 该试验评估布林妥莫单抗联合达沙替尼和类固醇的可行性与结局。
  • 入组65岁及以上Ph+或Ph样急性淋巴细胞白血病(伴达沙替尼敏感融合/突变)患者,可为新诊断或复发/难治。
  • 诱导为达沙替尼/泼尼松;第56天未缓解者接受布林妥莫单抗再诱导,缓解者接受3周期布林妥莫单抗/达沙替尼缓解后治疗及达沙替尼/泼尼松维持。
  • 所有患者接受鞘内甲氨蝶呤中枢神经系统预防共8剂;第28天以8色流式细胞术中央评估可测量残留病。
  • 共入组24例符合条件的新诊断Ph+急性淋巴细胞白血病患者,中位年龄73岁(范围65-87岁);试验注册号NCT02143414。

主要发现

  • 该联合方案安全可行。
  • 中位随访2.7年,3年总生存率为87%(95%CI 64-96),3年无病生存率为77%(95%CI 54-90)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出需要更长随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Novel treatment strategies are needed for the treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in older patients. This trial evaluated the feasibility and outcomes with the anti-CD19 bispecific T-cell-engaging antibody, blinatumomab, in combination with dasatinib and steroids. Patients 65 years of age or older with Ph+ or Ph-like ALL (with dasatinib-sensitive fusions/mutations) were eligible and could be newly diagnosed or relapsed/refractory. Induction therapy consisted of dasatinib/prednisone. Patients not achieving response by day 56 proceeded to blinatumomab reinduction therapy. Patients achieving response with induction or reinduction therapy proceeded to blinatumomab/dasatinib postremission therapy for 3 cycles followed by dasatinib/prednisone maintenance. All patients received central nervous system prophylaxis with intrathecal methotrexate for a total of 8 doses. Response was assessed at days 28, 56, and 84 and at additional time points based on response parameters. Measurable residual disease was assessed centrally by 8-color flow cytometry at day 28. A total of 24 eligible patients with newly diagnosed Ph+ ALL were enrolled with a median age of 73 years (range, 65-87 years). This combination was safe and feasible. With a median of 2.7 years of follow-up, 3-year overall survival and disease-free survival were 87% (95% confidence interval [CI], 64-96) and 77% (95% CI, 54-90), respectively. Although longer follow-up is needed, these results are encouraging, and future trials are building on this backbone regimen. This trial was registered at www.clinicaltrials.gov as #NCT02143414.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Advani AS, Moseley A, O'Dwyer KM, et al. Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia. Blood Adv. 2023. PMID: 36322825. doi:10.1182/bloodadvances.2022008216

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。